HPV Genotype Attribution and Disease Burden of Anal Cancer in China

Launched by FUDAN UNIVERSITY · Oct 31, 2024

Keywords

ClinConnect Summary

This clinical trial, titled "HPV Genotype Attribution and Disease Burden of Anal Cancer in China," aims to learn more about the human papillomavirus (HPV) and its connection to anal cancer in China. Researchers want to find out how common HPV is in patients with anal cancer, what types of HPV are involved, and how this disease affects different groups of people in terms of their age, gender, and health history. This study is important because it can help us understand the overall impact of anal cancer in China and guide future prevention and treatment efforts.

To be eligible for this trial, participants must have a confirmed diagnosis of anal cancer and should not have received radiation or chemotherapy before providing samples for the study. Unfortunately, people with HIV or those who have weakened immune systems, such as after an organ transplant, cannot participate. If you join the trial, you can expect to provide a sample for testing and contribute to valuable research that may improve the understanding and treatment of anal cancer in the future. The trial is currently not recruiting participants, but it represents an important step in addressing this health issue in China.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • (1) Patients diagnosed with anal cancers, (2) Patients without radiation or chemotherapy prior to specimen collection;
• Exclusion Criteria:
• • (1) Patients with HIV infection, (2) Patients with immunosuppression after solid organ transplantation, (3) Those who do not agree to specimen collection and testing, (4) For retrospective study cases, those who without specimen.